Add to Basket
|+1 404 474 4654|
|+1 888 205 9894 (TF)|
V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) antibody
|Synonyms||BRAF1, RAFB1, B-RAF1, FLJ95109, MGC126806, MGC138284, RMIL, C-RMIL, B-Raf, braf1, rafb1, b-raf1, BRAF|
Human, Mouse (Murine)
Alternatives ELISA, Immunofluorescence (IF), Immunohistochemistry (IHC), Western Blotting (WB)
|2 references available|
|Price||363.00 $ Plus shipping costs $45.00|
|Availability||Will be delivered in 3 to 4 Business Days|
|Immunogen||Purified recombinant fragment of human BRAF expressed in E. Coli.|
BRAF: v-raf murine sarcoma viral oncogene homolog B1, also known as BRAF1. RAFB1. B-RAF1. FLJ95109. Entrez Protein NP_004324. It is the main effectors recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway. B-Raf contains three consensus Akt phosphorylationsites (Ser364, Ser428, and Thr439). B-Raf is a key regulatory molecule of the mitogen-activated protein kinase kinase (MEK), it has a long amino-terminal region,the region is essential for homo-dimerization of B-Raf and hetero-dimerization of B-Raf and c-Raf at the plasma membrane, followed by phosphorylation of Thr118 in the amino-terminal B-Raf-specific region. Notably, in calcium ionophore-stimulated HeLa cells, B-Raf could propagate signals to MEK under the basal level of GTP-Ras. Expression of Raf-B is highly restricted with highestlevels in the cerebrum and testes and defects in braf are involved in a wide range of cancers. The BRAF gene mutation is frequently detected in papillary thyroid carcinoma,melanocytic nevi, primary cutaneous melanomas and colorectal cancers.
Synonyms: BRAF1, RAFB1, B-RAF1, FLJ95109
Western Blotting: 1/500 - 1/2000.
Immunohistochemistry: 1/200 - 1/1000.
Immunofluorescence: 1/200 - 1/1000.
ELISA: Propose dilution 1/10000.
Not yet tested in other applications.
Determining optimal working dilutions by titration test.
|Buffer||Ascitic fluid containing 0.03% sodium azide.|
|Preservative||0.03% sodium azide|
|Storage||Store at 4℃, for long term storage, store at -20℃.|
|Restrictions||For Research Use only|
Riesco-Eizaguirre, Gutiérrez-Martínez, García-Cabezas et al.: "The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane." in: Endocrine-related cancer, Vol. 13, Issue 1, pp. 257-69, 2006 (PubMed).
Di Nicolantonio, Martini, Molinari et al.: "Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 26, Issue 35, pp. 5705-12, 2008 (PubMed).
|Hosts||Rabbit (34), Mouse (25), Chicken (1)|
|Reactivities||Human (56), Monkey (6), Dog (Canine) (3), Mouse (Murine) (1), Rat (Rattus) (1)|
|Applications||Western Blotting (WB) (46), ELISA (39), Immunohistochemistry (IHC) (24), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)) (13), Immunofluorescence (IF) (6), Dot Blot (Dot) (5), Flow Cytometry (FACS) (3), Functional Studies (Func) (1)|
|Epitopes||C-Term (2), Internal Region (2), Ser578 (2), Thr400 (2), pSer445 (2), pSer601 (2), pThr400 (2), pThr439 (2), pThr598 (2), AA 10-22 (1), AA 405-524 (1), AA 754-765 (1), Center, Ser364 (1), N-Term (1), Ser364 (1), Ser428 (1), Ser445 (1), Ser601 (1), Ser728 (1), Thr372 (1), Thr439 (1), Thr598 (1), pThr598, pSer601 (1)|